NewsBenzingaLantheus Holdings anuncia el primer paciente dosificado en el ensayo registracional de fase 2/3 SPARROW NCT07831824, que evalúa LNTH-2401 Lantheus Holdings anuncia el primer paciente dosificado en el ensayo registracional de fase 2/3 SPARROW NCT07831824, que evalúa LNTH-2401 Benzinga 2026.09.28 12:04 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Equal-Weight on Sonoco Products, Lowers Price Target to $53 Piper Sandler Maintains Neutral on WaFd, Lowers Price Target to $31 VinFast Says Real Estate Could Cover Its EV Cash Burn Wells Fargo Maintains Overweight on Silgan Hldgs, Lowers Price Target to $52 Piper Sandler Maintains Neutral on First Finl Bankshares, Lowers Price Target to $33 $1000 Invested In Extra Space Storage 20 Years Ago Would Be Worth This Much Today
